Skip to main content
Clinical Trials/NCT06258993
NCT06258993
Recruiting
Not Applicable

Increasing Physical Activity Among Breast Cancer Survivors: Use of the ORBIT Model to Refine and Test a Novel Approach to Exercise Promotion Based on Affect-regulation (Study 2)

Dartmouth-Hitchcock Medical Center1 site in 1 country85 target enrollmentApril 16, 2024

Overview

Phase
Not Applicable
Intervention
Core Exercise Promotion Program
Conditions
Breast Cancer
Sponsor
Dartmouth-Hitchcock Medical Center
Enrollment
85
Locations
1
Primary Endpoint
Average Minutes of Daily Moderate-vigorous Physical Activity Measured Using the ActiGraph wGT3X-BT Accelerometer at 6 Weeks Follow-up
Status
Recruiting
Last Updated
2 months ago

Overview

Brief Summary

The goal of this clinical trial is to test the effect of an affect-based exercise prescription on moderate-vigorous physical activity participation among survivors of breast cancer who completed primary treatment within the last 5 years. The main questions it aims to answer are:

  1. Do at least 50% of participants assigned to the affect-based exercise prescription engage in ≥90 minutes of moderate-vigorous physical activity by the end of 12-weeks follow-up?
  2. What level of satisfaction do breast cancer survivors who receive the affect-based exercise prescription report relative to breast cancer survivors who receive an effort-based exercise prescription.
  3. What proportion of participants assigned to the affect-based exercise prescription stay enrolled in the study relative to the number of participants who stay enrolled in the effort-based exercise prescription.

All participants will:

  • Be assigned to either the Affect-based exercise prescription or the Effort-based exercise prescription.
  • Participate in two meetings with a member of the study team meant to help them get started increasing weekly exercise. These meetings are the same for all participants.
  • Be asked to wear an activity monitor and respond to brief surveys for 10 straight days at 4 points in time: Baseline, 2weeks, 6weeks, and 12weeks.
Registry
clinicaltrials.gov
Start Date
April 16, 2024
End Date
July 1, 2026
Last Updated
2 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Courtney J. Stevens

Assistant Professor of Psychiatry

Dartmouth-Hitchcock Medical Center

Eligibility Criteria

Inclusion Criteria

  • ≥18 years old
  • Within 5 years of completing primary cancer treatment (surgery, chemotherapy, and radiation) for Stage 0-III breast cancer
  • \<60 mins/week moderate-vigorous physical activity (MVPA) with no major changes for the past 6- months
  • Own an Android or iPhone smartphone (or tablet) and willing to use it to complete app-based surveys during assessment periods
  • Willing to wear the ActiGraph monitor during assessment periods
  • Access to internet to complete REDCap survey assessments

Exclusion Criteria

  • Non-English speaking/not able to read English
  • Evidence of major contraindications for exercise (informed by the 2020 Physical Activity Readiness-Questionnaire (PAR-Q)+)
  • Currently pregnant
  • History of severe mental illness or currently taking mood stabilizing medications (antipsychotics, anticonvulsants, or lithium)
  • Evidence of moderate-severe depressive symptoms (indicated by a score≥ 10 on the Patient Health Questionnaire-8)
  • Evidence of moderate-severe cognitive impairment (indicated by a score \< 3 on a 6-item cognitive screener)
  • Evidence of clinically significant substance use as indicated by a score of ≥ 2 on the CAGE- AID screener.

Arms & Interventions

Affect-based Exercise Prescription (Affect-Rx)

Intervention: Core Exercise Promotion Program

Affect-based Exercise Prescription (Affect-Rx)

Intervention: Affect-based exercise prescription

Effort-based Exercise Prescription (RPE-Rx)

Intervention: Core Exercise Promotion Program

Effort-based Exercise Prescription (RPE-Rx)

Intervention: Effort-based exercise prescription

Outcomes

Primary Outcomes

Average Minutes of Daily Moderate-vigorous Physical Activity Measured Using the ActiGraph wGT3X-BT Accelerometer at 6 Weeks Follow-up

Time Frame: 6-weeks follow-up assessment.

The research grade ActiGraph wGT3X-BT model is a valid measure of physical activity intensity and duration among multiple populations, including breast cancer survivors. Minutes of moderate-vigorous physical activity will be collected from the ActiGraph wGT3X-BT every day for 10-days. Average minutes of moderate-vigorous physical activity completed per day of valid wear time will be calculated.

Average Minutes of Daily Moderate-vigorous Physical Activity Measured Using the ActiGraph wGT3X-BT Accelerometer at 2 Weeks Follow-up

Time Frame: 2-weeks follow-up assessment.

The research grade ActiGraph wGT3X-BT model is a valid measure of physical activity intensity and duration among multiple populations, including breast cancer survivors. Minutes of moderate-vigorous physical activity will be collected from the ActiGraph wGT3X-BT every day for 10-days. Average minutes of moderate-vigorous physical activity completed per day of valid wear time will be calculated.

Average Minutes of Daily Moderate-vigorous Physical Activity Measured Using the ActiGraph wGT3X-BT Accelerometer at 12 Weeks Follow-up

Time Frame: 12-weeks follow-up assessment.

The research grade ActiGraph wGT3X-BT model is a valid measure of physical activity intensity and duration among multiple populations, including breast cancer survivors. Minutes of moderate-vigorous physical activity will be collected from the ActiGraph wGT3X-BT every day for 10-days. Average minutes of moderate-vigorous physical activity completed per day of valid wear time will be calculated.

Secondary Outcomes

  • Satisfaction With Study Participation as Measured by the Participant Satisfaction Questionnaire(12-weeks follow-up assessment.)
  • Study Retention at 2-weeks Follow-up(2-weeks follow-up assessment.)
  • Study Retention at 6-weeks Follow-up(6-weeks follow-up assessment.)
  • Study Retention at 12-weeks Follow-up(12-weeks follow-up assessment.)
  • Acceptability of the Affect-regulated Exercise Prescription Measured Using the Treatment Acceptability and Preferences (TAP) Measure(12-weeks follow-up assessment.)
  • Change in Voluntary Exercise Behavior Measured Using The Voluntary Exercise Questionnaire(Baseline, 6-weeks follow-up, and 12-weeks follow-up.)
  • Change in Physical Activity Category Completed in the Past Month Measured Using the Stanford Leisure-Time Activity Categorical Item (L-Cat)(Baseline, 6-weeks follow-up, and 12-weeks follow-up.)
  • Change in Physical Activity using The International Physical Activity Questionnaire (IPAQ)-Short Form(Baseline, 6-weeks follow-up, and 12-weeks follow-up.)

Study Sites (1)

Loading locations...

Similar Trials